LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

36.22 -2.45

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

36.14

Max

36.55

Belangrijke statistieken

By Trading Economics

Inkomsten

-20M

-85M

Winstmarge

-867.293

Werknemers

316

EBITDA

-21M

-94M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+47.28% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

327M

2.9B

Vorige openingsprijs

38.67

Vorige sluitingsprijs

36.22

Nieuwssentiment

By Acuity

50%

50%

175 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 sep 2025, 22:41 UTC

Belangrijke Marktbewegers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sep 2025, 16:04 UTC

Belangrijke Marktbewegers

Upexi Shares Climb on Solana Gains

12 sep 2025, 15:03 UTC

Belangrijke Marktbewegers

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

12 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 20:09 UTC

Winsten

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sep 2025, 19:23 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:16 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:03 UTC

Marktinformatie

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sep 2025, 18:59 UTC

Marktinformatie

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sep 2025, 18:38 UTC

Marktinformatie
Winsten

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sep 2025, 18:33 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sep 2025, 18:22 UTC

Marktinformatie

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sep 2025, 16:56 UTC

Marktinformatie

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sep 2025, 16:22 UTC

Winsten

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sep 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 16:19 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

12 sep 2025, 16:11 UTC

Winsten

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sep 2025, 15:37 UTC

Marktinformatie

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sep 2025, 15:22 UTC

Marktinformatie

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sep 2025, 15:07 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 14:34 UTC

Marktinformatie

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sep 2025, 14:10 UTC

Marktinformatie

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sep 2025, 13:58 UTC

Marktinformatie

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sep 2025, 13:58 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 13:57 UTC

Winsten

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sep 2025, 13:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 sep 2025, 13:56 UTC

Marktinformatie

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sep 2025, 13:54 UTC

Marktinformatie

U.S. Natural Gas Recovers Ground -- Market Talk

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

47.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.33 USD  47.28%

Hoogste 60 USD

Laagste 48 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

175 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat